Stromal microenvironment processes unveiled by biological component analysis of gene expression in xenograft tumor models by Yang, Xinan et al.
PROCEEDINGS Open Access
Stromal microenvironment processes unveiled by
biological component analysis of gene expression
in xenograft tumor models
Xinan Yang
1†, Younghee Lee
1†, Yong Huang
1, James L Chen
2, Rosie H Xing
3,4*, Yves A Lussier
1,4,5*
From 2010 AMIA Summit on Translational Bioinformatics
San Francisco, CA, USA. 10-12 March 2010
Abstract
Background: Mouse xenograft models, in which human cancer cells are implanted in immune-suppressed mice,
have been popular for studying the mechanisms of novel therapeutic targets, tumor progression and metastasis.
We hypothesized that we could exploit the interspecies genetic differences in these experiments. Our purpose is to
elucidate stromal microenvironment signals from probes on human arrays unintentionally cross-hybridizing with
mouse homologous genes in xenograft tumor models.
Results: By identifying cross-species hybridizing probes from sequence alignment and cross-species hybridization
experiment for the human whole-genome arrays, deregulated stromal genes can be identified and then their
biological significance were predicted from enrichment studies. Comparing these results with those found by the
laser capture microdissection of stromal cells from tumor specimens resulted in the discovery of significantly
enriched stromal biological processes.
Conclusions: Using this method, in addition to their primary endpoints, researchers can leverage xenograft
experiments to better characterize the tumor microenvironment without additional costs. The Xhyb probes and R
script are available at http://www.lussierlab.org/publications/Stroma.
Background
Characterizing the tumor microenvironment is essential as
it relates to clinical prognoses, metastatic potential, and
treatment-related outcomes [1]. Innovations in cell label-
ing techniques and small-animal in vivo imaging have
enabled investigators to phenotype the microenvironment
and cancer cell interactions. However, genome-wide
expression analyses of the tumor and its microenviron-
ment have not kept pace. Tearing apart cancer cells from
stromal tissues in whole tissue expression requires time
consuming and costly laser microdissection of the tumor
before RNA extraction [2,3]. Computational methods pre-
viously have been proposed as a means of subtraction out
the stromal signal [4]. Yet this method simply eliminates
genes which have conflated expression levels, however it
does little to elucidate the tumor microenvironment.
In this paper, we describe a computational method of
exploiting interspecies differences in the mouse tumor
xenograft model in which human cancer cells are grown
in immune-suppressed mice. This model is popular for
studying the mechanisms of preclinical drug trials,
tumor progression and the development of metastasis.
Mouse xenografts consist of both human tumor cells
and mouse stromal tissues [5], thus differential gene
expression derived from human expression arrays are
generally implicitly attributed to the cancer cells [6,7].
However, cross-hybridization of human chip probes
with homologous mouse genes may result in a mixed
gene expression signal where deregulated mice stromal
* Correspondence: hxing@bsd.uchicago.edu; ylussier@medicine.bsd.uchicago.
edu
† Contributed equally
1Section of Genetic Medicine, Dept. of Medicine, University of Chicago, IL,
USA
3Dept. of Pathology and of Radiation and Cellular Oncology; University of
Chicago, IL, USA
Full list of author information is available at the end of the article
Yang et al. BMC Bioinformatics 2010, 11(Suppl 9):S11
http://www.biomedcentral.com/1471-2105/11/S9/S11
© 2010 Yang et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.genes in xenograft tumor models are being jointly mea-
sured along with the human cancer genes. Up to date,
functional categories (Gene Ontology terms) enriched in
t h eg e n ee x p r e s s i o no fw h o l et u m o rx e n o g r a f t sh a v e
neglected the impact of cross-species hybridization.
Tumor/stromal interactions have been examined by
modeling the diffusion of the nutrients in the stroma,
invasion of single cells into the stroma, and characteriz-
ing the function of the stromal elements [8-10]. To our
knowledge, no studies have specifically focused on iden-
tifying mouse stromal signals in human gene arrays.
However, unsurprisingly, a few groups have identified
cross-species signals in multiple species chips [11,12].
Others and us have designed pan-viral arrays comprising
of species-probes for over 1000 species on one chip for
diagnostic purposes [12,13]. In collaboration with others,
we have demonstrated that statistically-based gene
enrichment approaches to these pan-viral arrays were
effective in increasing the species-specific signal and
consequently the diagnostic accuracy of these pan-
microbial arrays [14]. The xenograft tumor expressed on
human arrays presents a multiple species problem.
Human probes were not designed to be species specific
and thus, the cross-hybridization is equally present in
Human expression arrays (if not more important) than
in pan-microbial arrays.
We hypothesized that we could identify stromal
microenvironment signals (Gene Ontology (GO) biologi-
cal processes) from deregulated genes using the human
array probes unintentionally cross-hybridizing with the
mouse homolog. This assumption is based on the obser-
vation that 1) t h em a j o r i t yo ft h ec r o s s - h y b r i d i z i n g
probes designed for human genes also target their
mouse homolog, and 2) the majority of Gene Ontology
[15] annotations for human and mouse homolog are
identical (Additional file 1: Suppl. Methods). Thus, in
this paper, we design an unbiased method to identify
and optimize the choice of cross-species hybridizing
probes. To test out this method, we compared the Gene
Ontology terms enriched in cross-hybridizing probes
with those derived from microdissected stromal
components.
Methods
We developed a two-stage method for deriving the
underlying biology of the tumor stromal microenviron-
ment that we call “biological component analysis”. It
is designed to enrich the gene expression signals in the
stromal component separately from the cancer cell com-
ponent of the tumor xenograft (Figure 1).
Datasets
The GO annotations and gene homolog for the human
genome were downloaded from the NCBI. Microarray
platform information for the Agilent 44k whole human
genome oligo microarray was obtained from the Gene
Expression Omnibus [16] (GEO:GPL6480; Additional
file 1: Suppl. Methods, Table A).
Simulating a xenograft model with human and mouse
RNA
In order to biologically determine cross-hybridizing
probes, the human and mouse universal reference RNAs
were obtained from ArrayIt (Sunnyvale, CA).
Array selection
For this study, we selected the Agilent 44k whole human
genome oligo microarray which allows for custom
design. The Agilent microarray is designed with one or
more 60-mer probes per gene rather than the more
complex Affymetrix probe-sets containing multiple
shorter (25-mer) probes voting for each gene (Addi-
tional file 1: Suppl. Methods, array preprocessing).
Determining probes of human arrays cross-hybridizing
with mouse RNA and the proportion of homologous
genes between species
Cross-species hybridizing (Xhyb) probes between
human and mouse RNA were determined by combining
a computational method (BLAST [17]) and a biological
method in which the channels of two arrays were inde-
pendently exposed to either (i) mouse RNA, (ii) human
RNA, or (iii) both. For simplicity, these genes are here-
after referred to as “Xhyb genes” whose probes were
highly expressed when exposed to mouse universal
RNAs but lower when exposed to human universal
RNAs. We hypothesized that the mouse-specific, and
thus stromal-specific, signals are enriched in these
cross-species hybridizing probes. From the identified
genes with only cross-species hybridizing probes, the
proportion of homologous genes between the two
species were calculated. This last step was important to
justify the GO enrichment studies conducted over
cross-hybridizing probes of the human array that were
used to produce sets of GO terms describing the biolo-
gical processes in the stroma (Additional file 1: Suppl.
Methods). The normalization model of microarray gene
expression on a log scale, noted as y,i nt h i sx e n o g r a f t
model is:
yc c ij i j i j ij Hs Hs Mm Mms ,, () ( ) =++ + +  (1)
where μ represents the overall mean value for a probe,
i, originally designed for its Homo sapiens (Hs)t a r g e t
(noted as μiHs)o rMus musculus (Mm) homolog if cross-
hybridizing (noted as μiMm). The notation c is the main
effect of a clinical phenotype, j,a d d i t i v et ot h ep r o b e
expression. The notation ε is the stochastic error [18]
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non-homologous cross-species hybridizing, and other
technological errors. Because the four-array experiment
was performed under the exact same conditions, we
ignored the array effect and array interaction effect in
the data extracted by the Agilent Feature Extraction
Software for the Agilent 4x44k array (4 arrays per slide).
Thus, in this case of cross-species hybridization, we can
assume that the distribution of the term (μiHs+ cjHS)i s
stochastic (centered at zero) and thus, part of the error
ε. Consequently, the equation for the expression of a
cross-hybridizing probe becomes:
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Where ε’ represents stochastic errors. Therefore, the
differential expression of a Xhyb probe between two
phenotypes, a and b, is really a stromal gene response
rather than a cancer cell response on a log scale:
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We make standard stochastic assumptions about the
errors ε, ε’ and ε”. As shown in Figure 2, when Xhyb
human probes are exposed to both human and mouse
RNA, their major expression levels reflect the expression
of their homologous mouse genes. Thus, the GO terms
enriched in these cross-species hybridizing human gene
Figure 1 Description of the Biological Component Analysis Part A: To derive the possible contribution of the stromal microenvironment
from the cross-hybridizing probes, we studied gene lists derived from xenograft models from the literature that used the same microarray
platform. Robust GO enrichment analyses[20] were conducted over (i) all genes differentially expressed between the experimental conditions, (ii)
the cross-hybridizing subset, or (iii) the remaining genes (A, Top Venn Diagram). Part B: We evaluated the cross-hybridizing genes enriched GO
terms with expert classified GO terms and with the gold standards from literature (Bottom Venn Diagrams). Legend: Hs: Homo sapiens;M m :Mus
musculus; P: Probe; GS: gold standard.
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gous mouse genes. In contrast, in the remaining deregu-
lated genes (remaining genes)t h a ta r ep u t a t i v e l y
enriched in cancer cell signal, the majority of gene
expressions were contributed by designed targets which
reflect the tumor biological processes of human tumor
tissues.
A stromal GO term is contributed by genes where
cross-species hybridization is more likely to occur as
presented in Table 1. Thus by selecting genes that are
differentially expressed between phenotypes and also
Xhyb, we identify a stromal-specific GO term that can
distinguish among phenotypes. This is because each of
the hybridizing probes of the human array expresses
only when it is exposed to mouse RNA in our biological
experiment. Thus the differentially expressed probe
between phenotypes reflects the dysregulation of its
homologous mouse target rather than the stochastic
effect or cancer effect.
Stromal effect among literature-reported stroma gene
lists (Figure 1A, Additional file 2: Suppl. Table 1)
Xenograft models of human cancer and mouse stroma
are generally analyzed using human arrays for deregu-
lated genes, and the expression profiles are generally
attributed to the human gene’s biological processes or
functions. To assess the stromal effect among the
reported tumor contributing genes, we searched the
PubMed resource by keywords “xenograft, Agilent, can-
cer, gene expression”. Two of the resulting publications
fit the criteria using the same platform (GEO:GPL6480)
as shown in Table 2. Among these two publications, a
glioblastoma [19] study was selected for further GO
enrichment analysis as it contained enough “literature-
reported genes” (Additional file 2: Suppl. Table 1). The
literature-reported genes, whose probes cross-hybridize
with mouse RNAs (Xhyb), were thereafter searched
using the available GenBank IDs or official gene
symbols.
Figure 2 A simulated visual model of differential genes expression in a xenograft experiment. The numbers in the plot are the simulated
gene symbols of differentially expressed probes. Legend: a, b: two sample groups; c: effect of interested; i: probe id; FC: fold change (Equation 1).
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cross-species GO terms
To identify the overrepresented biological processes, the
Entrez Gene ID for annotated probes were inputted into
the Bioconductor package GOstats [20], followed by the
enrichment of GO biological process (BP) terms con-
ducted in four ways. In Enrichment a (conventional
enrichment of genes derived from Xenograft models),
the list of literature-reported genes (defined in previous
paragraph, Additional file 2: Suppl. Table 1) were com-
pared to the entire gene set of the 44k Agilent microar-
ray. In Enrichment b (enrichment of putative stromal
signal), the Xhyb subset of the literature-reported genes
were compared to all Xhyb genes in the microarray that
we had identified. In Enrichment c (enrichment of can-
cer cells signal), the remaining (non-Xhyb) subset of
reported genes were compared to the remaining (non-
Xhyb) genes in the microarray. In Enrichment d
(enrichment of more specific stromal signal), the subset
of reported genes whose probes cross-hybridized with
their mouse homolog were compared to all the genes
with cross-hybridized probes on the array. Note that
since we could not know which cross-hybridizing probes
targeted which homolog on the entire array without
experimental evidence, test d) used all genes with cross-
hybridizing probes as the background resulting in an
estimated statistic. Alternatively, approach b) uses an
evaluation by proxy based on the observation that the
majority of mouse GO Annotations were identical to
human GO Annotations, and the majority of the cross-
hybridizing genes target their corresponding mouse
homolog (Additional file 1: Suppl. Methods). For each
described Tests (above Tests “a”, “b”, “c”, “d”), a
“conditional” enrichment analysis [20] was conducted.
This “conditional” hypergeometric test allows for (i)
controlling false positives results resulting from genes
inherited in the hierarchical structure of GO instead (ii)
increasing the robustness of results from small gene lists
because it follows a bottom-up testing method. This
method tests the leaves of the GO graph, and then it
removes all genes annotated at significant child-terms
from the parent-term’s gene list before testing the terms
whose descendant have already been tested.
Evaluation of the methodology (Figure 1B)
We validated our methodology using two gold standards;
each one was based on an independently published list of
biological processes (GO terms) enriched in differentially
expressed genes derived from microarray experiments of
cancer stroma microdissected out of whole tumors [2,3].
The Fisher’s exact test was performed between the GO
terms of (i) each “gold standard” and those (ii) overrepre-
sented among the “Xhyb genes”. This was based on the
assumption that between the xenograft model and the
human environment, the stromal response to human
cancer has a shared phenotype leading to a shared Gene
Ontology annotation. Thus, the stromal response in
xenograft models could be applied to cancer study. In
particular, the first gold standard (GS1) contained 61 bio-
logical processes in the differentially expressed breast
stromal genes that were identified by comparing laser
microdissected stromal tissues (adjusted to cancer) with
paired normal epithelium [3].T h es e c o n dg o l ds t a n d a r d
(GS2) compared gene expression profiles of breast tumor
stroma captured by laser capture microdissection, and
reported the overrepresented GO terms associated with
poor-prognosis, good-prognosis and mixture-outcome,
respectively [2]. These 107 biological processes derived
from the whole tumor with poor prognosis were used as
t h es e c o n dg o l ds t a n d a r db e c a u s es a m p l e sw i t hp o o r
prognosis are more representative for characterization of
stromal signatures [2]
The network of the enriched GO biological process
terms and those in the two gold standards were visua-
lized using Bioconductor packages Rgraphviz and
GOstats. An additional evaluation for the union of
Table 1 Deregulated human genes and their contributed Gene Ontology in a xenograft model
Gene Ontology Enrichment from the Differentially Expressed Genes Expression of Significantly Differentially Expressed Probes in
Human Array
Xhyb probes Remainders
Biological process chiefly attributable to mouse stromal cells ci,jMm » ci,jHs ci,jHs is stochastically distributed
Biological process chiefly attributable to human cancer cells ci,jMm is stochastically distributed ci,jMm « ci,jHs
Biological processes enriched in the experiment Both ci,jMm and ci,jHs are stochastically distributed
This table describes the relationship between deregulated genes and their contributed Gene Ontology in a xenograft model, using human microarray. Legend: ci,
jHs is the main effect of a clinical phenotype j on a Homo sapiens (Hs) gene targeted by a probeset i; where ci,jMm is the main effect of a clinical phenotype j on a
Mus musculus (Mm) gene cross-hybridized by a probeset i.
Table 2 Previous xenograft cancer studies using the
Agilent GPL6480 whole human microarray
Cancer Sample Reported Genes
Glioblastomas
(GBM)[20]
10 GBMs
xenografts
78 genes differentially expressed
between the first and later GBM
xenograft generations.
Colon cancer
[6]
3-4 xenografts
per group
28 genes deregulated in mutant tumor
xenografts versus the control tumor
xenografts.
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justed cumulative conditional hypergeometric test) were
performed as described in (Additional file 1: Suppl.
Method and Additional file 2: Suppl. Table 2. The Xhyb
probes and R script can be downloaded from http://
www.lussierlab.org/publications/Stroma.
Results
Identification of Xhyb probes
After a sequence similarity search of a human probe
with mouse RNA sequence databases and the subse-
quent biological cross-species expression experiment,
cross-species hybridizing probes were identified and
additional species-specific probes were designed by our
research group for the same gene. As shown in the left
plot of Figure D in Additional file 1: Suppl. Methods,
we examined the top 18% (notated as BGS2.18) of the
absolute expression of mouse probes when exposed to
human RNA because it had the highest F-score (preci-
sion=40%, recall=25%) together with the 3
rd theoretical
prediction model (noted as M-Xhyb3). We examined
multiple conditions in the M-Xhyb3 and developed an
optimized model (right plot of Figure D, Additional file
1: Suppl. Methods). Using this optimized model, we
adjusted the parameter, x,o fB G S 2 .T h i sp r o c e s s
resulted in 6,200 Xhyb probes involving 5,300 mouse
genes from GPL7202 and 5,900 Xhyb probes involving
4,900 human genes from GPL6480, respectively.
Xhyb genes found in published deregulated genes from
xenograft models
The identified Xhyb subset of the literature-reported
tumor deregulated genes is listed in Additional file 2: S.
T a b l e1 .N o t et h a tt h e r ew e r em a n yg e n e st a r g e t e db y
multiple Agilent probes. In such cases, reported genes
with only one cross-mouse hybridizing probe were
annotated as “Xhyb deregulated genes” while reported
genes with both Xhyb and none-Xhyb probes were con-
sidered as “possible Xhyb deregulated genes”. Details are
g i v e ni nA d d i t i o n a lf i l e2 :S .T a b l e3 - 4 .F u r t h e r m o r e ,
among the 17 identified cross-mouse hybridizing human
probes that were reported by literature in Additional file
2: S. Table 3, 13 probes targeted their mouse homologs
(Additional file 2: S. Table 5) as predicted by the
BLASTN algorithm [17] with default parameters. Several
biological processes associated with stromal cells were
significantly (p<1%) enriched only among the Xhyb
deregulated genes. For example, it has been previously
shown that implanted tumors developed intensive angio-
genesis with vascular endothelial growth factor (VEGF)
induction in the stroma [21]. Accordingly, we found
that positive regulation of vascular endothelial growth
factor receptor signalling pathway was significantly
enriched among the Xhyb deregulated genes (p=0.004),
suggesting a different stromal/tumor cell cross-talk and
was further demonstrated by differences in angiogenesis
and in necrosis [19].
Evaluation
The biological process terms associated with cross-
hybridizing probes that targeted mouse homologs
(Methods, Enrichment d) significantly overlapped with
the known stromal gold standard terms as defined in
Methods, Evaluation of the methodology section. As
s h o w ni nF i g u r e3 ,f o u ro u to ft w e l v eG Ot e r m so v e r -
lapped with the GS1 (Fisher’s Exact Test p=7x10
-6). In
contrast, none of the 15 GO terms enriched among
remaining non-cross-hybridized genes (Methods,
Enrichment c) matched the GS1 (Figure 3A). Examin-
ing the second gold standard, three Xhyb genes enriched
GO terms (Methods, Enrichment d)o v e r l a pw i t hG S 2
(Fisher’s exact tested p=0.001). On the other hand, there
was only one overlap from the remaining gene enriched
GO terms (Methods, Enrichment c,p=0.26) (Figure
3B). Moreover, an alternative evaluation focusing on the
genes with cross-hybridizing probes (Methods, Enrich-
ment b) also resulted in significant overlap between the
two gold standards (p-value=0.07 and 0.01 respectively)
for Xhyb gene enriched GO terms. Noteworthy, there
was no overlap between Xhyb gene enriched GO terms
(Methods, Enrichment b and Enrichment d)a n dt h e
whole tumor annotations from the subset with good
prognosis. This finding corroborates the hypothesis that
biological process annotations associated with poor
prognosis contain more stromal components.
Figure 4 visualizes the graphical relationship of the
identified BP terms and two gold standards (Additional
file 2: S. Table 6). The biological process, “regulation of
behaviour”, is of interest as a root term in 4 out of the 7
identified terms that also have overlap with GS2. This
may suggest that tumor stromal actions or reactions are
in response to external or internal stimuli through the
regulation of chemotaxis. Note that 11 out of the 12
identified GO terms are the child nodes of the stromal
gold standard terms (Additional file 3: Suppl. Figure 1).
In addition, as presented in Additional file 4: S. Figure
2 panel a, deregulated Xhyb genes (Enrichment d, cyan
circles) are significantly better at predicting biological
processes of stromal cells when compared to the the
remaining genes (Enrichment c) and the full reported
gene list (Enrichment a) annotations in both studies.
Conversely, Additional file 4: S. Figure 2 panel b shows
that the remaining deregulated genes (Enrichment c,
orange triangles) or the full gene list (Enrichment a,
blue squares) are better at predicting biological pro-
cesses associated to cancer cells.
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Limitations and future studies. This study focused on
human probes that were inadvertently cross-hybridized
with mouse RNAs. The confounded expression of 5,000
human and mouse genes can thus be assessed; however,
these measures are limited in that they are not genome-
wide. The platform-specific cross-species hybridizing
probes, thus, limits our study as we are indirectly mea-
suring the stromal microenvironment effects as com-
pared to the direct measurements that could arguably
be obtained with species-specific mouse probes.
For future studies, we plan to use knowledge extracted
from the literature to further refine the interpretation
using BioMedLEE [22] in a high-throughput manner. Our
Figure 3 Comparison of the gold standards [2,3] of stromal biological process (BP). The BP terms enriched among the genes with cross-
hybridizing probes that target mouse homologs (Homo-Xhyb), and among the remaining genes for glioblastoma deregulation [19] were
respectively compared with gold standards. Legend: a, b: two sample groups; c: effect of interested; i: probe id; FC: fold change (Equation 1).
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human microarrays and therefore can only reveal part of
the stromal signatures. A more complete view of stromal
signatures in xenograft model should be investigated using
mouse-specific probes. To further identify microenviron-
ment factors associated with tumor progression and clini-
cal prognosis, we are currently developing a novel
methodology to dissect cancer and stromal signature using
a xenograft model of head and neck cancer.
Conclusions
In this paper, we introduced a novel design to detect
biological processes of the stroma using human arrays
with probes of which approximately 25% cross-hybri-
dized with mouse genes. We also conclude that the
majority of our identified cross-hybridized genes target
their corresponding homolog. Although human and
mouse RNA gene expression are confounded in this
subset of probes, we have demonstrated that an appro-
priately performed Gene Ontology enrichment analysis
can identify significant stroma-associated GO terms by
evaluating our findings with GO annotations from pre-
vious laser capture microdissections of the stroma.
These results suggest that our method may be a reason-
able alternative to laser microdissection in a specially
designed chip. Our results also suggest that human chip
probes cross-hybridizing with mouse genes are, in fact,
over-annotated with stroma-associated biological pro-
cesses. This leads us to believe that xenograft gene
expression contain confounded cell signals and stromal
cell signals which must be accounted for. An additional
benefit of this methodology is that from a cost
Figure 4 The network of the Xhyb enriched BP terms and two gold standards. A full network including all identified BP terms are given in
Additional file 3: Suppl. Figure 1.
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additional stromal knowledge from current xenograft
tumor arrays without needing to perform further
in vivo/in vitro experiments. In future studies, we intend
to examine these cross-species enrichments for biologi-
cal interactions between cancer cells and stromal cells,
an important initiative of the National Cancer Institute
Tumor Microenvironment Think Tank [23].
Additional material
Additional file 1: Supplementary Methods
Additional file 2: Supplementary Tables 1-6S. Table 1: Xhyb subset
of previous xenograft studies reported cancer deregulated genes.S.
Table 2: The significant (p<1%) GO terms among the deregulated genes
in a published glioblastoma xenograft model.S. Table 3: Xhyb subset of
the differential expressed genes in a previous xenograft study and their
corresponding probes in the Agilent array (GPL6480).S. Table 4: Xhyb
subset of the 28 deregulated genes reported by a previous colon tumor
xenograft study and their corresponding Agilent array (GPL6480) probes.
Genes in bold are those identified as Xhyb. According to the author
(Gouye et al 2008), HT-29-derived 5M21 which displayed a constitutive
invasive behavior in type I collagen, while TATI was shown in this study
to be a major autocrine and transforming factor produced by HT-29-
derived 5M21 cells to control colon cancer cell invasion and metastasis.S.
Table 5: The human probes in S. Table 3 that target their mouse
homologs.S. Table 6: The identified stromal associated GO terms
(hypergeometric test p-value<1%) that also reported by two gold
standards using laser microdissection technology.
Additional file 3: Supplementary Figure 1 Significantly enriched
(p<1%) BP terms among the genes with mouse homologous cross-
hybridizing probes, and their overlapping with two gold standards. The
identified BP terms with their nearest parent-terms of the gold standard
are listed below the network graph.
Additional file 4: Supplementary Figure 2 Comparison of the
overrepresented biological processes (BPs) derived from three GO en-
richment tests for the reported gene list. Different data points are the
proxy recall and precision under a serial of thresholds for GO enrichment
test. Panel a shows that in predicting stromal processes, the reported
Xhyb subset of deregulated genes performs better than either the
remain-ing genes or the full reported gene list, since only the precision-
recall predictions from reported Xhyb genes (cyan circles) are significant
(proxy p<5%). Panel b shows that the Xhyb subset of deregulated genes
are the worst at predicting cancer processes compared to the other two
kinds of gene lists with lower precision and recall.
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